Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Risk adjusted net present value: What is the current valuation of Merck's Tulisokibart?
Tulisokibart is a monoclonal antibody commercialized by Merck, with a leading Phase III program in Ulcerative Colitis;Crohn's Disease (Regional Enteritis)....
Data Insights
Tulisokibart by Merck for Ulcerative Colitis: Likelihood of Approval
Tulisokibart is under clinical development by Merck and currently in Phase III for Ulcerative Colitis. According to GlobalData, Phase III...